Neoadjuvant Pyrotinib plus Trastuzumab and Chemotherapy for Stage I-III HER2-Positive Breast Cancer: A Phase II Clinical Trial.
Juncheng XuhongXiaowei QiPeng TangLinjun FanLi ChenFan ZhangXuanni TanWenting YanLing ZhongCheng HeYan LiangLin RenMinghao WangYi ZhangJun JiangPublished in: The oncologist (2020)
This study showed that in HER2-positive operable or locally advanced breast cancer, the tpCR rate of P + EC-TH neoadjuvant therapy was about twice as high as that of EC-TH neoadjuvant therapy reported in other trials, with tolerable side effects.
Keyphrases
- locally advanced
- rectal cancer
- phase ii
- clinical trial
- neoadjuvant chemotherapy
- squamous cell carcinoma
- positive breast cancer
- phase ii study
- radiation therapy
- open label
- lymph node
- double blind
- study protocol
- stem cells
- randomized controlled trial
- placebo controlled
- young adults
- bone marrow
- replacement therapy
- cell therapy
- metastatic breast cancer